Wedbush Forecasts Stronger Earnings for IDEAYA Biosciences

Key Points

• Wedbush has increased its Q3 2025 earnings per share forecast for IDEAYA Biosciences from ($0.97) to ($0.94).
• In its latest quarterly report, IDEAYA Biosciences reported a loss of ($0.88) EPS, missing analysts' expectations of ($0.85), but revenue of $6.00 million exceeded the anticipated $3.48 million.
• IDEAYA's stock ratings are largely positive, with a consensus rating of "Moderate Buy" and a price target of approximately $48.09 according to MarketBeat data.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Equities researchers at Wedbush raised their Q3 2025 EPS estimates for IDEAYA Biosciences in a report released on Tuesday, August 5th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.94) per share for the quarter, up from their prior estimate of ($0.97). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences' Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.61) EPS, Q1 2026 earnings at ($1.06) EPS, Q2 2026 earnings at ($1.10) EPS, Q3 2026 earnings at ($1.13) EPS, Q4 2026 earnings at ($1.15) EPS, FY2026 earnings at ($4.44) EPS, FY2027 earnings at ($4.05) EPS, FY2028 earnings at ($3.16) EPS and FY2029 earnings at ($0.78) EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts' expectations of $3.48 million. The business's revenue for the quarter was up NaN% on a year-over-year basis. During the same period in the previous year, the company earned ($0.68) earnings per share.

A number of other research analysts have also commented on IDYA. JPMorgan Chase & Co. upped their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a research note on Monday, July 28th. TD Cowen began coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a "buy" rating on the stock. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their price objective for the company from $57.00 to $30.00 in a research note on Wednesday, July 9th. Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price objective for the company. Finally, The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a report on Thursday, July 10th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $48.09.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA traded down $0.47 on Thursday, hitting $22.63. 292,499 shares of the company's stock were exchanged, compared to its average volume of 1,150,906. The firm has a 50-day moving average price of $22.48 and a 200-day moving average price of $20.34. The company has a market cap of $1.98 billion, a P/E ratio of -5.97 and a beta of 0.09. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $40.74.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds have recently modified their holdings of IDYA. Geode Capital Management LLC raised its holdings in IDEAYA Biosciences by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after purchasing an additional 43,226 shares in the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of IDEAYA Biosciences by 33.2% during the first quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company's stock worth $189,000 after acquiring an additional 2,884 shares during the last quarter. Rhumbline Advisers grew its position in shares of IDEAYA Biosciences by 9.6% during the first quarter. Rhumbline Advisers now owns 124,437 shares of the company's stock worth $2,038,000 after acquiring an additional 10,876 shares during the last quarter. Palumbo Wealth Management LLC grew its position in shares of IDEAYA Biosciences by 65.8% during the first quarter. Palumbo Wealth Management LLC now owns 22,402 shares of the company's stock worth $367,000 after acquiring an additional 8,893 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C grew its position in shares of IDEAYA Biosciences by 5.5% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after acquiring an additional 142,000 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.